Adipose Tissue-derived Mesenchymal Stem Cell (AD-MSC) Therapy for the Treatment of Sexual Function Impairment in Female

PHASE2RecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

December 30, 2025

Conditions
Sexual Dysfunction Female
Interventions
BIOLOGICAL

Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency

"* Patients in the two groups will receive two autologous AD-MSC administrations: the group A on day 0 and day 90 ± 7; the group B on day 180 ± 14 and day 270 ± 14.~* Dose: 1.0 x 106 cells/kg patient bodyweight.~* Route: intravenous infusion~ADSCs were collected after the third passage. On the day of transplantation, the ADSCs were harvested, washed twice with NaCl 0.9%, counted and resuspended in NaCl 0.9% in a total volume of 20 ml. Each participant received a dose of 1x10\^6 cells/kg body weight infused through the intravenous route within 30 minutes before being discharged after 24 hours"

Trial Locations (1)

100000

RECRUITING

Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi

All Listed Sponsors
lead

Vinmec Research Institute of Stem Cell and Gene Technology

OTHER